Table 1 Clinical characteristics of participants during the study period
From: Plasma proteome and metabolome characterization of an experimental human thyrotoxicosis model
Characteristics | baseline | 4 weeks (L-T4)a | 8 weeks (L-T4)a | 12 weeks | 16 weeks | β (SD)b | Logc | P value(SD)d |
|---|---|---|---|---|---|---|---|---|
Age, years | 27.8 (3.8) | 27.8 (3.8) | 27.8 (3.8) | 27.8 (3.8) | 27.8 (3.8) | – | – | – |
BMI, kg/m2 | 24.1 (2.4) | 24.1 (2.4) | 24.1 (2.4) | 24.1 (2.4) | 24.1 (2.4) | – | – | – |
FT4, pmol/L | 13.2 (1.4) | 28.6 (6.5) | 25.9 (5.7) | 11.5 (1.5) | 12.8 (1.5) | – | – | <0.001e |
FT3, pmol/L | 5.27 (0.51) | 9.19 (2.01) | 8.92 (2.25) | 4.61 (0.33) | 4.86 (0.55) | 2.76 × 10–1 (8.22 × 10–3) | no | 7.43 × 10–25 (4.28 × 10–24)f |
TSH, mU/L | 2.104 (1.017) | 0.017 (0.029) | 0.007 (0.007) | 2.298 (1.309) | 2.177 (0.897) | –1.35 × 10–1 (6.42 × 10–3) | yes | 7.26 × 10–21 (2.02 × 10–20)f |
SHBG, nmol/L | 30.2 (10.2) | 50.6 (16.2) | 55.9 (16.3) | 36.3 (11.8) | 29.3 (9.3) | 1.41 × 10–2 (9.11 × 10–4) | yes | 3.41 × 10–10 (1.03 × 10–9)f |
Cystatin C, mg/L | 0.68 (0.06) | 0.79 (0.08) | 0.86 (0.12) | 0.71 (0.07) | 0.68 (0.06) | 4.19 × 10–3 (2.35 × 10–4) | yes | 8.26 × 10–9 (1.10 × 10–8)f |
Serum glucose, mmol/L | 5.18 (0.35) | 5.22 (0.42) | 5.26 (0.39) | 5.09 (0.31) | 5.18 (0.57) | 5.76 × 10–3 (1.62 × 10–3) | no | 2.91 × 10–1 (1.38 × 10–1) |
Insulin, μU/L | 8.35 (3.63) | 7.94 (4.32) | 7.78 (3.62) | 8.33 (4.06) | 8.07 (3.38) | –1.29 × 10–3 (1.14 × 10–3) | yes | 6.58 × 10–1 (2.29 × 10–1) |
HDL-cholesterol, mmol/L | 1.43 (0.27) | 1.21 (0.20) | 1.23 (0.25) | 1.46 (0.29) | 1.42 (0.37) | –1.30 × 10–2 (8.89 × 10–4) | no | 1.33 × 10–5 (1.54 × 10–5)f |
LDL-cholesterol, mmol/L | 2.70 (0.72) | 2.15 (0.57) | 2.27 (0.53) | 2.91 (0.75) | 2.76 (0.79) | –4.18 × 10–2 (1.96 × 10–3) | no | 2.91 × 10–8 (6.08 × 10–8)f |
Cholesterol, mmol/L | 4.53 (0.75) | 3.81 (0.61) | 4.06 (0.61) | 5.04 (0.70) | 4.61 (0.68) | –5.87 × 10–2 (2.24 × 10–3) | no | 3.05 × 10–10 (6.84 × 10–10)f |
Triglycerides, mmol/L | 1.26 (0.76) | 1.14 (0.58) | 1.29 (0.56) | 1.31 (0.63) | 1.35 (0.82) | –1.96 × 10–3 (6.06 × 10–4) | yes | 3.08 × 10–1 (1.65 × 10–1) |
ALT, μkatal/L | 0.51 (0.21) | 0.38 (0.10) | 0.65 (0.42) | 0.61 (0.29) | 0.50 (0.14) | –4.30 × 10–3 (9.65 × 10–4) | yes | 9.99 × 10–2 (7.00 × 10–2) |
AST, μkatal/L | 0.49 (0.41) | 0.34 (0.14) | 0.43 (0.17) | 0.43 (0.14) | 0.43 (0.23) | –2.03 × 10–3 (1.30 × 10–3) | yes | 4.67 × 10–1 (2.37 × 10–1) |
GGT, μkatal/L | 0.41 (0.09) | 0.45 (0.11) | 0.49 (0.11) | 0.45 (0.15) | 0.43 (0.11) | 6.84 × 10–4 (8.20 × 10–4) | yes | 6.55 × 10–1 (3.18 × 10–1) |
Total bilirubin, μmol/L | 12.5 (8.4) | 12.6 (8.7) | 13.5 (7.3) | 11.9 (6.4) | 11.9 (7.3) | 1.56 × 10–3 (1.18 × 10–3) | yes | 5.83 × 10–1 (2.35 × 10–1) |
Direct bilirubin, μmol/L | 2.86 (1.35) | 3.04 (1.35) | 3.28 (1.24) | 2.84 (1.03) | 3.03 (1.39) | 3.00 × 10–3 (5.14 × 10–4) | yes | 1.06 × 10–1 (6.69 × 10–2) |
Complement C3, g/L | 1.15 (0.27) | 1.21 (0.16) | 1.17 (0.11) | 1.10 (0.14) | 1.11 (0.14) | 4.49 × 10–3 (5.06 × 10–4) | no | 2.38 × 10–2 (1.75 × 10–2)f |
Complement C4, g/L | 0.24 (0.06) | 0.25 (0.05) | 0.24 (0.05) | 0.23 (0.05) | 0.24 (0.05) | 9.81 × 10–4 (1.38 × 10–4) | no | 3.09 × 10–2 (2.94 × 10–2)f |